

2024 INTERIM RESULTS CONFERENCE CALL

TREATING PATIENTS BEYOND BORDERS

AUGUST 2024





Disclaimer



By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following:

The information in this presentation has been prepared by representatives of Antengene Corporation Limited (the "Company" and, together with its subsidiaries, the "Group") for use in presentations by the Group for information purpose. No part of this presentation will form the basis of, or be relied on in connection with, any contract or commitment or investment decision.

Certain statements contained in this presentation and in the accompanying oral presentation, may constitute forward-looking statements. Examples of such forward-looking statements include those regarding investigational drug candidates and clinical trials and the status and related results thereto, as well as those regarding continuing and further development and commercialization efforts and transactions with third parties. Such statements, based as they are on the current analysis and expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Company's control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the global and regional regulatory environment in the jurisdictions in which the Company's does business, market volatility, fluctuations in costs and changes to the competitive environment. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. In the case of forward-looking statements regarding investigational drug candidates and continuing further development efforts, specific risks which could cause actual results to differ materially from the Company's current analysis and expectations include: failure to demonstrate the safety, tolerability and efficacy of the Company's drug candidates, final and quality controlled verification of data and the related analyses, the expense and uncertainty of obtaining regulatory approval, the possibility of having to conduct additional clinical trials and the Company's prospectus published onto the websites of the Company and The Stock Exchange of Hong Kong Limited and the and uncertainties that are described in the Company's prospectus published onto the websites of the Company and The Stock Exchange of Hong Kong Limited and the announcements and other disclosures we make from time to time. The reader should not place undu

Forward-looking statements are sometimes identified by the use of forward-looking terminology such as "believe," "expects," "may," "will," "could," "should," "shall," "risk," "intends," "estimates," "plans," "predicts," "continues," "assumes," "positioned" or "anticipates" or the negative thereof, other variations thereon or comparable terminology or by discussions of strategy, plans, objectives, goals, future events or intentions.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. The information set out herein may be subject to updating, revision, verification and amendment and such information may change materially.

This presentation and the information contained herein is highly confidential and being furnished to you solely for your information and may not be reproduced or redistributed in any manner to any other person, in whole or in part. In particular, neither the information contained in this presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in any jurisdiction which prohibits the same except in compliance with applicable securities laws. This presentation and the accompanying oral presentation contains data and information obtained from third-party studies and internal company analysis of such data and information. We have not independently verified the data and information obtained from these sources.


By attending this presentation, you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Group and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Group.

2024 1H OVERVIEW




Antengene Priorities Today





Cash and Bank Balances of RMB1,024mm to Advance Pipeline Development and Initiatives

APAC Commercial Business and R&D: Catalyzing Growth with XPOVIO[®] Commercial Progress and ATG-008 Advancements



Global R&D: Portfolio of Globally First-/Best-in-Class Pipeline Poised to Deliver on Multiple Value Creating Milestones in the Next 12 to 24 Months




4 Glob	bal Clinical Stage Programs	
	ATG-022 Claudin 18.2 ADC Phase II Dose Expansion Ongoing	 ✓ Preliminary Data from Phase I Dose Escalation (Efficacious Dose Range of 1.8-2.4 mg/kg): ORR of 40% (2/5; 1 CR [Claudin 18.2 ultra-low expression] and 1 PR among 5 gastric cancer patients) ✓ Preliminary Data from On-going Phase II Dose Expansion (As of August 21st, 2024): ORR of 41.7% (5/12) and DCR of 100% (12/12) in gastric cancer patients who at least underwent their first tumor assessment after study treatment among 21 patients enrolled) I responder is a patient with ultra-low CLDN18.2 expression (IHC - 2+ ≤5%)
the second secon	ATG-037 CD73 Small Molecule Inhibitor Phase I Dose Escalation Completed; Proceeding to Dose Optimization/Expansion	 4 PRs observed in CPI-pretreated patients (2 melanoma patients, 2 non-small cell lung cancer patient), demonstrating the potential to reverse CPI resistance ✓ Demonstrated an excellent safety profile in dose escalation
1-4-1-4-1-4-1-4-1-4-1-4-1-4-1-4-1-4-1-4	ATG-101 PD-L1/4-1BB Bispecific Antibody Phase I Dose Escalation Ongoing	 Durable responses at starting doses; No liver toxicities observed Observed a PR in a patient with metastatic colon adenocarcinoma (microsatellite stability biomarker (MSS; classified as cold tumors), liver metastasis, and three prior lines of therapy)
	ATG-031 CD24 Monoclonal Antibody Phase I Dose Escalation Ongoing	 A total of 19 late stage cancer patients have been treated To date, no dose-limiting toxicities (DLTs) have been observed Stable disease (SD), with objective tumor shrinkage, and clinical improvement have been observed

Technology Platform and Pre-clinical Innovations: Advancing with the AnTenGager™ TCE Platform, ATG-201 (CD19/CD3 TCE), and ATG-042 (PRMT5-MTA)



Technology Platform and Pre-clinical Programs

AnTenGager™ T Cell Engager (TCE) Platform



CLINICAL PIPELINE OVERVIEW





GLOBAL RIGHTS ASSETS

Global Rights Pipeline with Transformational Potentials



Assets	Target <i>(Modality)</i>	Pre-clinical	Phase I	Phase II	Antengene Rights	Partner
ATG-022	Claudin 18.2 (ADC)	Monotherapy for Onc <i>(CLINCH)</i>				
ATG-037	CD73 (Small Molecule)	Monotherapy <u>+</u> pembrolizumab fo	or Onc/Hem <i>(STAMINA)</i>	with Clinical Collaboration		
ATG-101	PD-L1/4-1BB (Bispecific Antibody)	Monotherapy for Onc/Hem <i>(PROB</i>	BE & PROBE-CN)		📢 Global	
ATG-031	CD24 (Monoclonal Antibody)	Monotherapy for Onc/Hem <i>(PERF</i>	ORM)			ANTENGENE
ATG-042	PRMT5-MTA (Small Molecule)	Onc/Hem			-	
ATG-201	CD19/CD3 (Bispecific Antibody)	B Cell Related Autoimmune Diseases				

ATG-022 Differentiated Anti-Claudin 18.2 ADC - Efficacy at Low Expression Levels


Claudin 18.2

- Tumor-associated antigen overexpressed in **esophageal**, **gastric**, **pancreatic cancers**
- To less extent in NSCLC, ovarian and colorectal cancers, head and neck carcinomas, etc.

Differentiated Potency


- Phase I Dose Escalation ORR of 40% (1 CR and 1 PR among 5 patients in efficacious dose range of 1.8-2.4 mg/kg) in Claudin 18.2 ultra-low expressing gastric cancer (IHC Staining 2+ ≤5%)
- Ongoing Phase II Dose Expansion ORR of 41.7% (5 PRs among 12 patients who had underwent at least their first tumor assessment after study treatment; One responder is a patient with ultra-low CLDN18.2 expression) and 100% DCR

ATG-022: A Potent Antibody-Drug Conjugate (ADC)





ATG-022 Outperforms Competitor Molecules with Unprecedented Efficacy in Claudin 18.2 Ultra-Low Gastric Cancer, Maximizing Commercial Potential ANTENGENE



Source: GLOBOCAN; Cao W, Xing H, Li Y, et al. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark Res. 2022 May 31,10(1):38; Baek, J. H., Park, D. J., Kim, G. Y., Cheon, J., Kang, B. W., Cha, H. J., & Kim, J. G. (2019). Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer. *Anticancer Research, 39*(12), 6973-6979. https://doi.org/10.21873/anticanres.13919;

ATG-022: Advancing Global Phase I/II "CLINCH" Trial in a Broad Spectrum of Solid Tumors



Phase II Dose Expansion Study Ongoing with Multiple Centers in Australia and the Mainland of China

Phase I: Dose Escalation

(Multiple Tumor Types without Pre-screening for Claudin 18.2 Expression Levels)

Primary Objectives:


Safety, tolerability. Define MTD and RP2D

Secondary Objectives: Evaluate preliminary efficacy (RECIST 1.1), measure ADA, CLDN18.2 expression

All solid tumors allowed to be enrolled, no requirement for Claudin 18.2 expression as enrollment criteria

Key Observations:

- 1 CR from 2.4mg/kg dose level (Ultra-low CLDN 18.2 expression)
- 1 PR from 1.8mg/kg dose level (CLDN 18.2 expression unknown)



Approximately 120 subjects, depending on the number of cohorts to be expanded. CLDN18.2+ tumors only. No prior CLDN18.2 agents

Phase II: Dose Expansion

Complete Response (CR) and Partial Response (PR) Detected in Dose Escalation Phase; Currently Enrolling Patients for the Dose Expansion Phase (21 Patients Enrolled)

ATG-022: Efficacy in All Claudin 18.2 Expression Levels Including From High to Ultra-low Expressors



ANTENGENE

Preliminary Efficacy (as of August 21st, 2024)

- Phase I (Multiple Tumor Types Without Pre-screening for CLDN18.2 Expression Levels): Dose escalation stage completed; RP2D at 2.4 mg/kg confirmed with SRC
 - 2 responders among 5 gastric cancer patients in the 1.8 mg/kg and 2.4 mg/kg cohorts (ORR of 40%; without pre-screening patients' Claudin 18.2 expression levels)
 - 1 CR from 2.4mg/kg dose level observed (ultra-low CLDN 18.2 expression) and 1 PR from 1.8mg/kg dose level observed (CLDN 18.2 expression unknown)*
- Phase II (Claudin 18.2 Expression Required): Enrollment is ongoing, 21 gastric cancer patients enrolled
 - 5 PRs out of 12 patients who at least underwent their first tumor assessment (including a patient with ultra-low CLDN18.2 expression)
 - 100% DCR (3 SDs with 28%, 26.5%, and 24% tumor shrinkages respectively)



* The sample obtained via punch biopsy from the patient's tumor was of insufficient quality due to significant areas of necrosis or contamination within the tissue. As a result, the pathologist was unable to accurately assess Claudin 18.2 expression levels

ATG-037: Potentially Best-in-Class CD73 Small Molecule Inhibitor





Best-in-Class Potential

- Completely blocks CD73 activity and overcomes "hook effect" commonly seen in anti-CD73 antibodies
- Rescues T-cell functions in high AMP conditions
- Demonstrated potential to reverse CPI-resistance in Phase I dose escalation study

Excellent Safety Profile

- No ATG-037 related toxicity identified in GLP toxicology studies
- Demonstrated a very clean safety profile during dose escalation
 - Most TEAEs are Grade 1-2 and did not require any dose modification
- No inhibition of CD39 and other related targets (up to 10 mM)






Adenosine Induces Immunosuppressive


Cell Types and Enhances Their Function

Broad Therapeutic Potential in Multiple Tumor Types



Monotherapy and Combination with Anti-PD-1, Pembrolizumab





Completed Phase I Dose Escalation; Proceeding to Phase II Dose Expansion Phase in Q3 2024


ATG-037 (CD73): Swimmer Plot in the Phase I "STAMINA" Trial



18

Preliminary Data (as of July 26th, 2024)

- 4 PRs observed in patients previously treated with a checkpoint inhibitor (CPI; 2 melanoma patients, 2 non-small cell lung cancer patient), demonstrating the potential to reverse CPI resistance
- ATG-037 demonstrated excellent safety profile in dose escalation stage and will proceed to dose expansion in Q3 2024



CC = Cervical Cancer; CCRCC = Clear Renal Cell Carcinoma; EC = Esophageal Carcinoma; MAM = Metastatic Adenocarcinoma; MESO = Mesothelioma; MM = Melanoma; MSCCCP = Metastatic Squamous Cell Carcinoma of Cutaneous Primary; NET = Neuroendocrine Tumor; NSCLC = Non-small cell lung cancer; OC = Ovarian Cancer; RCA = Renal Cell Carcinoma; SCLC = Small Cell Lung Cancer; TCA = Thymic Carcinoma; UC = Uterine Cancer

ATG-101 (Xirestomig), a Potentially Best-in-class PD-L1/4-1BB Bispecific Antibody Offers Potential to Overcome PD-(L)1 Resistance



How can ATG-101 Overcome PD-(L)1 Resistance?						
Add a T Cell Booster	Creating an "On-switch"	Complementary Mechanism of PD-L1/4-1BB to render "Cold" tumors "Hot"				
By combining with a 4-1BB agonist	By using a bi-specific antibody to create a "trimer-induced-on-switch" to reduce 4-1BB driven liver tox	PD-L1 ⁺ Cancer Cell PD-L1 → Activate Exhausted T-cells				
Maximize PD-L1 Binding	To Render Tumors "Hot"	Increase CD8+ T-cells activity				
ATG-101's PD-L1/4-1BB arm affinity ratio of 65 ensures high PD-L1 receptor occupancy	By increase CD8+ T-cell activity and downstream dendritic cell and NK cell activity	<pre></pre>				
		Strong T Cell Activation				




Phase I, Multi-center, Open Label, Dose-finding Study Ongoing in Multiple Centers in the U.S., Australia and China*

Phase Ia: Dose Escalation	Phase Ib: Dose Expansion
Primary Objectives: Safety, tolerability RP2D definition (60 subjects)	Planning to evaluate efficacy and safety in multiple cohorts including CPI-resistant populations as well as "cold tumors"
Secondary Objectives: Evaluate standard efficacy, pharmacology, immunology, biomarkers, exploratory measurements (ADA, TME, biodistribution)	 CPI-exposed patients: 2 cohorts CPI-naive patients: 6 solid tumor cohorts



No Liver Toxicities Observed in the Dose Escalation Studies, with Partial Response (PR) and Durable Stable Diseases (SDs) Noted; Dose Escalation to be Completed in 1H 2025 ATG-031 (Anti-CD24 mAb): Novel Macrophage Activating Approach via Blocking CD24-Siglec10 and Enhancing Macrophage-Mediated Phagocytosis (MMP)





ATG-031: Advancing Through Phase I "PERFORM" with Key Milestones Ahead



Multi-center, Open Label, Ongoing in the U.S.*				
Phase Ia: Dose Escalation	Phase Ib: Dose Expansion			
Primary Objectives: Safety, tolerability. Define MTD and RP2D	RP2D dose evaluation as monotherapy or combo with chemotherapy or immunotherapy			
Secondary Objectives: Evaluate preliminary efficacy and pharmacology				

19 Late-Stage Cancer Patients Have Been Treated in the Phase I Dose Escalation of "PERFORM" Trial with No Dose-Limiting Toxicities (DLTs) Observed; Stable Disease (SD), Objective Tumor Shrinkage, and Clinical Improvement Have Been Noted; Targeting Phase I Data Readout in 1H 2025

* Key study sites include: The University of Texas MD Anderson Cancer Center, the University of California San Francisco, the University of Colorado, and Yale University Cancer Center MTD = maximally tolerated dose, RP2D = recommended Phase II dose



APAC RIGHTS ASSETS

APAC Rights Assets: Pipeline of Commercial or Near NDA Stage Drugs with First-in-class/Best-in-class Potential



Antengene Assets Target (Modality) Indication **Pre-clinical** Phase I Phase II Phase III/Pivotal NDA Commercialization Partner Riahts Combo with dexamethasone (MARCH) The Mainland of China NDA Approved Combo with dexamethasone (STORM) - Partner's Pivotal Trial in the US US, EU, UK, IL, SK, SG, AU, TW, HK & MY NDA Approved **R/R Multiple Myeloma** Combo with bortezomib and dexamethasone (BENCH) In Preparation for sNDA Submission Combo with bortezomib and dexamethasone (BOSTON) - Partner's Pivotal Trial in the US US, EU, UK, IL, CA, SG, AU, TW & MY sNDA Approved Monotherapy (SEARCH) sNDA Approved in The Mainland of China on June 28th, 2024 ATG-010 XPO1 APAC¹ Saryopharm (Selinexor) (Small molecule) R/R Diffuse Large B-cell Monotherapy (SADAL) - Partner's Pivotal Trial in the US* US, IL, SG, SK & TW sNDA Approved Lymphoma Combo with R-GDP (DLBCL-030) **Myelofibrosis** Combo with ruxolitinib (MF-034) Monotherapy (SIENDO) Maintenance Therapy for Endometrial Cancer Monotherapy (EC-042) - Partner's Pivotal Trial in the US Cervical Cancer and Celgene ATG-008 mTORC1/2 君实生物 Other Advanced Solid Combo with toripalimab (TORCH-2)** TopAlliance (Onatasertib) (Small molecule) Bristol Myers Squibb Tumors **Clinical Collaboration** Company Partner Trials⁴ Antengene Trials³ Partner Global Trials in Antengene Region Registrational Trial

Antengene has rights for Greater China (The Mainland of China, Hong Kong, Taiwan, Macau), Australia, New Zealand, South Korea, and the ASEAN Countries;
 Antengene has rights for Greater China, South Korea, Singapore, Malaysia, Indonesia, Vietnam, Laos, Cambodia, the Philippines, Thailand and Mongolia;
 Most advanced trial status in Antengene territories and the trials are responsible by Antengene;
 Most advanced trial status in Antengene territories and the used of the trials of t

* SADAL Study (DLBCL US Trial) approval is under the accelerated approval pathway; ** Investigator-initiated trials; R/R: relapsed/refractory; Hem/Onc: hematological malignancies and solid tumors; R-GDP: Rituximab, Gemcitabine, Dexamethasone & Cisplatin; GemOx: Gemcitabine, Oxaliplatin; ICE: Ifosfamide, Carboplatin, Etoposide

AU: Australia; CA: Canada; EU: Europe; IL: Israel; MY: Malaysia; SG: Singapore; SK: South Korea; TW: Taiwan; UK: United Kingdom; US: United States;

⁴ Most advanced trial status in partner territories in the rest of the world and the trials are conducted by our licensing partners

ATG-008 (Onatasertib): A Novel Second Generation mTORC1/2 Inhibitor




Summary of ATG-008 (Onatasertib)

- Mammalian target of rapamycin (mTOR), a core component of two structurally distinct protein complexes (mTORC1 and mTORC2), regulates different cellular processes and is upregulated in multiple types of tumors
- When mTORC1 is inhibited, mTORC2 is upregulated. This increase in mTORC2 activity generates a surplus of phosphorylated PKB/AKT which, despite mTORC1 inhibition, inhibits apoptosis and promotes cell proliferation via alternative pathways
- mTORC1 and mTORC2 has to be inhibited simultaneously for good antitumor efficacy

First- and Best-in-Class Potential

- Second generation mTOR inhibitor, targeting both TORC1 and TORC2
- Demonstrated comprehensive mTOR inhibition, which could minimize development of resistance due to mTORC2 upregulation
- Encouraging initial clinical data in combination with anti-PD-1 mAb in the treatment of relapsed or metastatic cervical cancer



Updated Encouraging Preliminary Data of ATG-008 (Onatasertib) in "TORCH-2" Trial

ANTENGENE

Encouraging Preliminary Data of ATG-008 (Onatasertib) in Both CPI-naïve and CPI-pre-treated Advanced Cervical Cancer Patient Cohorts

ATG-008 (mTORC1/2i) in combination with toripalimab (Anti-PD-1 mAb)

Overall Response Rate (ORR)

53.3%

Efficacy Evaluable Population 2L+ CPI-naïve Cervical Cancer (16/30) **Disease Control Rate (DCR)**

86.7%

Efficacy Evaluable Population 2L+ CPI-naïve Cervical Cancer (26/30) Huge Unmet Medical Needs in Advanced Cervical Cancer

297,000+

Cervical Cancer Patients in China

109,000+

New Cervical Cancer Cases in China Each Year

Overall Response Rate (ORR)

22.2%

Efficacy Evaluable Population 2L+ CPI-treated Cervical Cancer (6/27) Disease Control Rate (DCR)

92.6%

Efficacy Evaluable Population 2L+ CPI-treated Cervical Cancer (25/27)

In Communication with the Regulators on a Registrational Pathway in Advanced Cervical Cancer

Enrollment is ongoing for "TORCH-2" trial, preliminary data as of August 20th, 2024

Promising Data from "TORCH-2" Study in CPI-naïve Cervical Cancer Patients

Deep and Durable Responses Were Observed Regardless of PD-L1 Expression Status



- As of August 20th, 2024, 30 2L+ CPI-naïve advanced cervical cancer patients who received ATG-008 at RP2D in combination with toripalimab had undergone at least one tumor assessment after study treatment
- The best overall response (BOR) was 6 complete responses (CR), 10 partial responses (PR), 11 stable diseases (SD), and 4 progressive diseases (PD)
- The overall response rate (ORR) was 53.3%, disease control rate (DCR) was 86.7%
- The ORR was 61.5% (8/13), 55.6% (5/9), and 37.5% (3/8) in PD-L1 positive, PD-L1 negative, and PD-L1 status not available (NA) patients, respectively




Preliminary data as of August 20th, 2024

The ORR data presented on this slide for ATG-008 in combination with toripalimab in CPI-naïve cervical cancer patients represents the Unconfirmed Best Overall Response

Encouraging Preliminary Results from "TORCH-2" Study in CPI-pretreated Cervical Cancer Patients



- As of August 20th, 2024, 27 2L+ CPI pre-treated advanced cervical cancer patients who received ATG-008 at RP2D in combination with toripalimab had undergone at least one tumor assessment after study treatment
- The best overall response (BOR) included 1 complete response (CR), 5 partial responses (PR), 17 stable diseases (SD), and 4 progressive diseases (PD)
- The overall response rate (ORR) was 22.2%, the disease control rate (DCR) was 92.6%
- Consistent safety profile with no new safety signals



Preliminary data as of August 20th, 2024

The ORR data presented on this slide for ATG-008 in combination with toripalimab in CPI-naïve cervical cancer patients represents the Unconfirmed Best Overall Response


PRE-CLINICAL PIPELINE OVERVIEW



Research and Development Focusing on New Drug Modalities: T Cell Engager

AnTenGager[™], a Novel "2+1" T Cell Engager Platform Enabling the Creation of TCEs with Enhanced Therapeutic Effect and Safety






T cell

- Proprietary CD3 sequences binding to a unique epitope of CD3
- Reduced binding of CD3+ T cells before disease-associated antigen (DAA) crosslinking
- Reduced risk of cytokine release syndrome and hook effect with enhanced efficacy
- Good developability (high expression yield, good thermostability and high stability/purity under different stress conditions)

Target Cell Destruction

The AnTenGager™ Platform is Designed to Address the Limitations of First Generation "1+1" T Cell Engagers (TCEs)






A Series of AnTenGager[™] TCEs with Transformational Potential



								ANTENGENE
Programs	Target	Target Indications	mAb Discovery	<i>In vitro</i> efficacy	In vivo efficacy	Developability	CMC/Tox	IND
ATG-201	CD19/CD3	B Cell Related Autoimmune Diseases						Expected in 2025 Q3
ATG-021	GPRC5D/CD3	Multiple Myeloma						
ATG-102	LILRB4/CD3	Acute Myeloid Leukemia (AML) & Chronic Myelomonocytic Leukemia (CMML)						
ATG-107	FLT3/CD3	Acute Myeloid Leukemia (AML)						
ATG-106	CDH6/CD3	Ovarian Cancer & Kidney Cancer						
ATG-110	LY6G6D/CD3	Microsatellite Stable (MSS) Colorectal Cancer						
ATG-112	ALPPL2/CD3	Solid Tumors						
ATG-105	DLL3/CD3	Small Cell Lung Cancer & Neuroendocrine Tumors						

ATG-201 is a Novel "2+1" CD19/CD3 AnTenGager™ TCE With Ability to Deeply Deplete B Cells for the Treatment of Autoimmune Diseases






Summary and Developmental Progress


- Pre-clinical candidate (PCC) was nominated for ATG-201, a potential best-in-class "2+1" CD19/CD3 AnTenGager TCE for the treatment of autoimmune diseases
- ATG-201 induced deep ex-vivo and in vivo B cell depletion with low risk of inducing CRS
- Potent efficacy was observed in systemic lupus erythematosus (SLE) and multiple sclerosis (MS) animal models
- ATG-201 demonstrated good developability
- IND-enabling study and CMC work is ongoing for ATG-201, with IND targeting Q3 2025

<u>B Cell in Lymph Nodes</u>




ATG-201 (CD19/CD3 AnTenGager™ TCE) Shows Comparable or Enhanced Naïve B Cell Depletion and Reduced Cytokine Release vs. Clinical Benchmarks

ANTENGENE




ATG-042, a Novel MTAP^{null}-Selective PRMT5 Inhibitor





Summary and Developmental Progress

- Pre-clinical candidate (PCC) was nominated for ATG-042, a potential best-in-class MTAP^{null} selective PRMT5 inhibitor
- ATG-042 preferably binds to the PRMT5-MTA over PRMT5-SAM complex, creates a synthetically lethal MTAP^{null} cancer-specific target, and leads to tumor cell death while sparing healthy cells
- ATG-042 demonstrated better DMPK/ADME profile, brain penetrability and in vivo efficacy compared with clinical benchmark, MRTX1719
- IND enabling study is ongoing for ATG-042, with **IND targeting H1 2025**



COMMERCIAL OVERVIEW



NRDL Inclusion and Commercialization Partnership with Hansoh Drives Growth Momentum for XPOVIO[®] in the Mainland of China




Reimbursements and Commercialization Partnership with Hansoh Provide a Foundation for Profitability of XPOVIO® in China



Accelerating Commercial Growth in APAC – Reimbursement and NDA Approvals Driving Strong Market Trajectory Across Key Markets






FINANCIAL OVERVIEW



2024 1H Financial Highlights (For the Six Months Ended June 30th, 2024)




Cash and Bank Balances of RMB1,024mm to Advance Pipeline Development and Initiatives










CLOSING REMARKS



2024 Marks a Year Full of Catalysts for Antengene

ANTENGENE





ANTENGENE CORPORATION LIMITED (SEHK: 6996.HK)

AUGUST 2024

THANK YOU

TREATING PATIENTS BEYOND BORDERS